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We report a case of chagasic meningoencephalitis re-
activation in a pregnant woman co-infected with Trypano-
soma cruzi and HIV that was successfully managed with 
benznidazole and highly active antiretroviral therapy. Early 
diagnosis enabled rapid specific treatment that improved 
the health of the patient and her baby.
Chagas disease, caused by the protozoan Trypanosoma cruzi, is transmitted to humans mainly by triatomine 
bugs (vector-borne route), through blood transfusions, or 
from mother to child through the placenta (transplacental 
route) (1). In patients co-infected with HIV, Chagas disease 
reactivation generally occurs in persons with CD4 T-cell 
counts <200 cells/mm3 and results in severe meningoen-
cephalitis or myocarditis (2). Confirmation of central ner-
vous system (CNS) reactivation requires T. cruzi detection 
in 1) cerebrospinal fluid, 2) brain tissue, or 3) blood, with 
neurologic manifestations and clinical response to parasiti-
cidal treatment (2). CNS reactivation is associated with a 
high mortality rate, and management consists of combin-
ing anti–T. cruzi drugs (benznidazole or nifurtimox) with 
highly active antiretroviral therapy (HAART) to favor im-
mune reconstitution (2,3).
Migration by persons from Chagas disease–endemic 
areas to vector-free urban centers, and changes in the epi-
demiologic profile of HIV, have led to a large overlap in the 
geographic distribution of the 2 infections (4). In fact, the 
prevalence of T. cruzi infection among HIV-seropositive 
patients from disease-endemic regions was found to be 
1.3% in Brazil and 1.9% in Spain (4,5).
Because safety of benznidazole in pregnancy has not 
been established (6), its use in treating pregnant women 
is contraindicated (7,8). Prevalence of vertical transmis-
sion of T. cruzi infection from immunocompetent women 
to their fetus varies from 0.1% to 18% among regions 
(7), and such transmission is strongly associated with the 
maternal blood-parasite load (7,9). However, patients co-
infected with HIV exhibit higher levels of parasitemia 
and a higher congenital transmission rate (10) than those 
who are not co-infected. Indeed, in our experience, 6 of 
7 co-infected pregnant women transmitted T. cruzi infec-
tion (11). We describe a noteworthy case-patient from 
that series, a woman who experienced reactivation of T. 
cruzi infection during the third trimester of pregnancy but 
did not transmit the parasite infection, probably because 
she received, without delay, treatment with benznidazole 
and HAART.
The Patient
A 33-year-old woman, who had been infected with 
HIV for 11 years, started receiving lamivudine, zidovu-
dine, and nevirapine at week 26 of pregnancy. At that time, 
CD4 cell count was 18 cells/mL. She had begun receiving 
HAART 1 year before pregnancy but abandoned treatment 
after a few months. Her compliance with treatment, labora-
tory tests, and follow-up was poor.
At week 32 of pregnancy, she was admitted to the 
hospital with clinical manifestations of intracranial hy-
pertension and meningoencephalitis (temporospatial 
disorientation, slurred speech, nausea and vomiting, and 
hemiparesis). A CNS mass was detected by magnetic res-
onance imaging (Figure). Results of serologic tests were 
negative for Toxoplasma gondii, Treponema pallidum, 
and hepatitis B and C viruses but positive for T. cruzi. 
Reactivation of Chagas disease was confirmed by a posi-
tive microhematocrit measurement (12). PCR targeted to 
T. cruzi kinetoplast DNA was positive, and quantitative 
PCR (qPCR) targeted to satellite T. cruzi DNA yielded 
308.9 parasite equivalents/mL of blood (13). The parasite 
genotype (discrete typing unit) detected by PCR strate-
gies was identified as TcV (14). Most probably, this pa-
tient acquired the infection by the vector-borne route in a 
highly disease-endemic province in Argentina where she 
had lived as a child.
Although data on benznidazole use in pregnancy are 
lacking, after an in-depth discussion of potential risks and 
benefits of the treatment, we concluded that, because of 
her severe clinical condition, treatment with benznida-
zole could be beneficial. Within 48 hours of the diagno-
sis, she received benznidazole (5 mg/kg/day, for 84 days) 
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without side effects. The patient showed rapid neurologic 
and clinical improvement. Parasitic loads, determined by 
qPCR, dropped rapidly (Figure). During treatment, results 
of the microhematocrit, PCR, and anti–T. cruzi serologic 
testing became negative for the parasite. Magnetic reso-
nance images showed substantial reduction of edema and 
the mass and reconstitution of the interventricular line 
without evidence of ventricular dilatation (Figure). Seven 
weeks after treatment initiation, cerebrospinal fluid was 
negative for T. cruzi by serologic testing, microhemato-
crit, and PCR.
At week 36 of gestation, the patient gave birth to a girl 
by elective cesarean section. The baby’s birthweight was 
low for gestational age (1,700 g, <3rd percentile), and her 
Apgar score was 7/8. The newborn was hospitalized for 32 
days. Microhematocrit and PCR results suggested that she 
had not acquired T. cruzi infection. This lack of infection 
was confirmed by means of serologic testing at 1 year of 
age, per current Chagas disease guidelines (12). Moreover, 
results of PCR for HIV and p24 antigen tests were negative 
in 2 different samples, enabling perinatal infection with 
HIV to be ruled out.
After delivery, the mother continued to receive 
HAART with benznidazole prophylaxis (5 mg/kg/day 3×/
week) for 6 months. A follow-up computed tomographic 
scan performed 14 months after delivery showed a favor-
able response. Moreover, serologic, parasitologic, and mo-
lecular studies remained negative for T. cruzi (Figure). To 
date, the patient continues to show erratic compliance with 
follow-up. As a consequence, immunologic recovery has 
not yet been achieved.
Conclusions 
Benznidazole is traditionally considered contraindicat-
ed in pregnancy because data that support its safety to the 
fetus are lacking (8). Nevertheless, because of the severe 
clinical picture of the patient, and the known lower risks 
of fetal toxicity in the second and third trimesters of preg-
nancy (6), treatment was administered on a compassionate 
basis. Among patients who have AIDS and Chagas disease 
reactivation with CNS involvement, early parasiticidal and 
HAART treatment can improve the poor prognosis (2,3). 
Cordova et al. (2) reported a mortality rate of 79% in a 
cohort of 15 patients with co-infection, with a median time 
of survival of 21 days after hospitalization. However, the 
researchers associated this high mortality rate with delayed 
diagnosis, because it took a median of 18 days to recognize 
the condition. In the patient reported here, the short interval 
(72 hours) between admission and initiation of benznida-
zole treatment may have improved the chances of a suc-
cessful outcome. Moreover, to our knowledge, the patient 
in this case has longest reported survival time after diag-
nosis of chagasic reactivation caused by HIV co-infection, 
with 7 years of follow-up (15).
Microhematocrit and PCR successfully demonstrated 
the presence and elimination of T. cruzi, and qPCR enabled 
the decrease in parasitic load to be monitored. T. cruzi TcV 
detected in peripheral blood was described as prevalent in 
the population from the Southern Cone (14). Notably, neg-
ative serologic results were achieved early after treatment, 
which is only usually seen in immunocompetent patients 
at the acute phase of disease or in recent congenital infec-
tions. The rapid negative seroconversion observed in this 
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Figure. Diagnosis, treatment, and 
prophylaxis monitoring of Trypanosoma 
cruzi infection in a pregnant woman 
and her daughter. The mother, who 
had chagasic encephalitis and AIDS, 
was treated with benznidazole (Bz). 
Results of ELISA were considered 
positive when R was >1.2);  results 
of IHA were considered positive 
when titers were >16. Po, positive; 
Ng, negative;  Nd, not determined; 
IHA, indirect hemagglutination assay; 
kDNA-PCR, kinetoplast DNA-PCR; 
qPCR, quantitative PCR (dynamic 
range of detection: 1–105 parasite 
equivalents/mL, amplification of 
efficiency 0.95, R 2 = 0.996); par/mL, 
parasites/mL of blood; NQ, positive 
but not quantifiable; MRI, magnetic 
resonance imaging; gwk, gestational 
week; pd, postdelivery; tmt, Bz 
treatment (5 mg/kg/d); HAART, highly 
active antiretroviral therapy; ppx, Bz 
prophylaxis (5 mg/kg/3× per week).
patient is uncommon. The continued seronegative results 
when her immune system presumably was reconstituted 
suggests strongly that she had an actual parasitologic cure.
Moreover, the baby’s weight at birth was low for ges-
tational age. Various reasons could explain the low birth-
weight, including the infectious status of the mother or the 
severe stress she was experiencing at the time of admission. 
Also, a potential effect of benznidazole for the baby cannot 
be fully ruled out. Nonetheless, the benefit to both mother 
and child clearly outweighed the risk. The baby did not ac-
quire either infection. 
This case illustrates that parasiticidal treatment may 
decrease parasitic load and prevent vertical transmission 
of T. cruzi, even in co-infected patients among whom a 
higher incidence of congenital infection and illness of 
newborns is observed (10). This result reinforces the idea 
that benznidazole has a role in the prevention of congeni-
tal transmission of Chagas disease. Therefore, studies that 
explore its safety and effectiveness during pregnancy may 
be warranted.
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